e-learning
resources
ERJ
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Macrolide effects on the prevention of COPD exacerbations
Yamaya Mutsuo, Azuma Arata, Takizawa Hajime, Kadota Jun-ichi, Tamaoki Jun, Kudoh Shoji
Source:
Eur Respir J 2012; 40: 485-494
Journal Issue:
August
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Yamaya Mutsuo, Azuma Arata, Takizawa Hajime, Kadota Jun-ichi, Tamaoki Jun, Kudoh Shoji. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012; 40: 485-494
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
Modulation of airway inflammation to prevent exacerbations of COPD
Source: Eur Respir Rev 2005; 14: 78-82
Year: 2005
Rosuvastatin influence on inflammatory and anti-inflammatory cytokines in blood in patients with chronic obstructive pulmonary disease
Source: International Congress 2017 – COPD management
Year: 2017
Antimicrobial peptide levels are linked to airway inflammation, bacterial colonisation and exacerbations in chronic obstructive pulmonary disease
Source: Eur Respir J , 49 (3) 1601328; DOI: 10.1183/13993003.01328-2016
Year: 2017
Rosuvastatin effects on systemic inflammation, oxidative stress and antioxidants in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline
Source: Annual Congress 2005 - Therapeutic options for COPD: present and future
Year: 2005
Exploitation of anti-inflammatory mechanisms for the treatment of severe asthma
Source: Annual Congress 2005 - Mechanisms of resolution of inflammation
Year: 2005
The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015
IL-33 blockade impacts mediators of persistence and exacerbation of chronic airway inflammation.
Source: International Congress 2018 – Novel drug targets for asthma and COPD
Year: 2018
Beyond corticosteroids: future prospects in the management of inflammation in COPD
Source: Eur Respir Rev 2011; 20: 175-182
Year: 2011
Effects of dexamethasone and anti-inflammatory drugs on inflammatory cytokines from bronchial epithelial cells of COPD patients
Source: International Congress 2015 – New insights into lung disease pathogenesis
Year: 2015
New anti-inflammatory activities of Alpha-1-Antitrypsin and their role in COPD
Source: Annual Congress 2005 - Protease-antiprotease revisited
Year: 2005
Mucin 1 downregulation associates with corticoid resistance in chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
Enhanced cytokine response to exercise in COPD
Source: Annual Congress 2006 - COPD and systemic inflammation
Year: 2006
The influence of statin supplementation on inflammatory markers in patients with chronic obstructive pulmonary disease
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015
Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: 325-331
Year: 2002
Interleukin-18 production and pulmonary function in COPD
Source: Eur Respir J 2008; 31: 287-297
Year: 2008
Mechanisms of impaired anti-bacterial Th1 responses in patients with chronic obstructive pulmonary disease
Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Year: 2018
Why short-term antibiotic use in AECB may influence long-term outcomes
Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept